A large pharmaceutical company was conducting a Phase 2 study for adults with obesity. They contracted 42 sites globally, including 6 Accellacare sites in the US to recruit for three cohorts and conduct the study.

Many participants on this study struggled to tolerate  the study drug without side effects. The study  didn’t allow for any variation in dose and offered no dietitian or lifestyle counselling, so many participants struggled with compliance and dropped from the  study altogether. 

Additionally, while the study enrolled well overall, many sites found it challenging to enroll enough male participants to meet their targets.

Accellacare Site Network was proactive in their recruitment strategy, reviewing each site’s electronic health records and reaching out to local primary care physicians to source eligible participants early. 

Because no nutrition or lifestyle counselling was available, our PIs actively reached out to participants to ask how they were handling the study drug and to provide counselling to those who may have early signs of adverse reactions in an effort to mitigate the severity.

Due to our early recruitment strategies, Accellacare sites achieved 137% of their enrolment target, placing 3 of the 6 Accellacare sites in the top 10 enrollers, study-wide. In fact, Accellacare contributed 26% to the total study’s US participant base, while only accounting for 14% of US sites, and we provided the last patient randomised for the study. This helped to offset participant dropouts, due to poor drug tolerance. Because of our early recruitment efforts, Accellacare sites moved from site activation to first patient screened within 1.5 days, on average. In addition, our screen failure rate was 8% lower than non-Accellacare sites.